Respiratory healthcare professionals’ views on long-term recommendations of interventions to prevent acute respiratory illnesses after the COVID-19 pandemic

Footnotes

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

Conflict of interest: KY reports grants from Vertex pharmaceuticals, grants from Gilead, outside the submitted work; GL reports grants and non-financial support from Vertex Pharmaceuticals, grants from Enanta Pharmaceuticals, grants from MedImmune, grants from DoseNTRX, outside the submitted work; JC reports grants and personal fees from Astrazeneca, grants and personal fees from Boehringer-Ingelheim, personal fees from Chiesi, grants and personal fees from Glaxosmithkline, grants from Gilead Science, grants and personal fees from Novartis, grants and personal fees from Insmed, personal fees from Zambon, personal fees from Janssen, personal fees from Grifols, outside the submitted work; MS reports grants, personal fees and non-financial support from GSKÐ grants and personal fees from Novartis, personal fees from Bohringer- Ingelheim, personal fees from Astra Zeneca, personal fees from Kamada, personal fees from Vertex pharmaceuticals, personal fees from Teva, non-financial support from Actelion, grants, personal fees and non-financial support from GSK, grants from Novartis, non-financial support from Rafa, personal fees from Zambon, personal fees from Bonus therapeutics, outside the submitted work.